MariTide: The Once-Monthly GLP-1/GIP-Antagonist Trial Explained

Direct Answer

MariTide (maridebart cafraglutide) is a real, investigational Amgen drug combining GLP-1 receptor agonism with GIP receptor antagonism, a genuinely contrarian approach compared to tirzepatide, which activates GIP rather than blocking it. It is not FDA-approved.

Real, Reported Phase 2 Results

MariTide produced mean weight reductions of up to 20% in participants with obesity without type 2 diabetes, and up to 17% in those with both obesity and type 2 diabetes, with once-monthly dosing. Participants with type 2 diabetes also saw HbA1c reductions of up to 1.6 percentage points.

A Real, Notable Feature: Durability

A real, distinguishing detail from Phase 2 data: much of the weight loss persisted after dosing stopped, and weight loss had not plateaued by the trial's end, genuinely different from the weight regain typically seen after discontinuing other GLP-1 medications.

Current, Real Status

MariTide has advanced to Phase 3 trials based on these Phase 2 results. It remains investigational and is not available by prescription.

References

• New England Journal of Medicine: MariTide Phase 2 trial results
• Applied Clinical Trials Online: MariTide Shows Up to 20% Weight Loss in Phase II Trial (2026)

How MariTide Compares to Other Investigational and Approved GLP-1s

For full detail on the approved medications in this comparison, see DietApp's tirzepatide and retatrutide medication pages. For retatrutide's own trial program, see DietApp's TRIUMPH trials page.

Frequently Asked Questions

Is MariTide the same as tirzepatide? No, they work in opposite directions on the GIP receptor, tirzepatide activates it, MariTide blocks it, while both activate GLP-1.

Can I get MariTide through a compounding pharmacy? No, it remains investigational and is not legally available outside clinical trials.

Why does monthly dosing matter? It's a real, practical convenience advantage over the weekly injections required by every currently approved GLP-1 medication.

When might MariTide be approved? Not established; it's currently in Phase 3, with real regulatory review still ahead.

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.